JSPR Q3 2024 Earnings — Jasper Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JSPRJasper Therapeutics, Inc.

$23M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$20M

Net Income

-$19M

EPS (Diluted)

$-1.24

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$99M

Total Liabilities

$16M

Stockholders' Equity

$84M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$20M	-$19M	-2.7%
Net Income	-$19M	-$18M	-6.2%